Evaluation of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): an open-label, multicentre, randomised, non-inferiority trial
2022 · The Lancet · 134 citations
https://doi.org/10.1016/s0140-6736(22)02078-5